Abstract:Abstract Background IBI362, a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week weight loss up to 6.4% at doses up to 6 mg in Chinese participants with overweight or obesity. We further explored the safety and efficacy of IBI362 dosed up to 9 mg and 10 mg. Methods Two high-dose cohorts from a randomized, placebo-controlled, multiple ascending dose study (NCT04440345) enrolled adults with overweight (body mass index [BMI] ≥24 kg/m 2) accompanied by hyperphagia and/or at least one comorbidity or obesity (BMI≥28 kg/m 2) from five study centers in China. Eligible participants were randomized 2: 1 within each cohort to receive once-weekly subcutaneous IBI362 or placebo. The cohorts and dose-escalation regimens were: 9 mg cohort (3 mg weeks 1-4; 6 mg weeks 5-8; 9 mg weeks 9-12) and 10 mg cohort (2.5 mg weeks 1-4; 5 mg weeks 5-8; 7.5 mg weeks 9-12; 10 mg weeks 13-16). The primary endpoints were safety and tolerability of IBI362. The secondary endpoints included changes from baseline in body weight, waist circumference and BMI. Results A total of 24 participants (mean age 37.9 years, body weight 81. 0 kg, BMI 30.5 kg/m 2) were enrolled, with eight randomly assigned to IBI362 and four to placebo in each cohort. One participant receiving IBI362 and two receiving placebo in the 10 mg cohort withdrew consent and quitted the study. The other 21 participants (87.5%) completed the treatment and the study. No serious adverse event (AE) was reported and all AEs were mild or moderate in severity. The most commonly-reported AEs included diarrhea, nausea, vomiting and decreased appetite (each reported in six participants [37.5%] receiving IBI362). Mean percent changes from baseline to week 12 in body weight were−11.7% for participants receiving IBI362 in the 9 mg cohort and−1.8% for participants receiving placebo (estimated treatment difference [ETD]: −9.8%; 95% confidence interval (CI): −14.4,−5.3; P = 0. 0002). Mean percent changes from baseline to week 16 in body weight were−9.5% for participants receiving IBI362 in the 10 mg cohort and−3.3% for participants receiving placebo (ETD: −6.2%; 95% CI: −11.5,−0.9; P = 0. 0243). Four participants (50%) receiving IBI362 in each cohort achieved≥10% weight loss and two (25%) receiving IBI362 in each cohort achieved≥15% weight loss during the study, while no participant receiving placebo achieved≥5% weight loss. In addition, waist circumference and BMI were markedly decreased in participants receiving IBI362. Conclusion IBI362 dosed up to 9 mg and 10 mg was both well tolerated and showed a favorable safety profile. IBI362 dosed with the 3-6-9 mg escalation regimen demonstrated extraordinary efficacy on 12-week weight loss, suggesting that IBI362 would be a promising weight loss drug as the next generation GLP-1-based dual agonist. Presentation: No date and time listed

Efficacy and safety of intragastric expandable oral capsules in adults with overweight or obesity: A randomized, double‐blind, placebo‐controlled trial

Development of an Ingestible Expandable Capsule for Weight Loss

Clinical Efficacy of Orlistat in Chinese Overweight and Obese Patients with Newly Diagnosed Type 2 Diabetes

ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 Mg and 10 Mg in Chinese Adults with Overweight or Obesity

Efficacy and Safety of a Chinese Herbal Medicine Formula (RCM-104) in the Management of Simple Obesity: A Randomized, Placebo-Controlled Clinical Trial

Mobile-Based Platform With a Low-Calorie Dietary Intervention Involving Prepackaged Food for Weight Loss for People With Overweight and Obesity in China: Half-Year Follow-Up Results of a Randomized Controlled Trial

667-P: IBI362 (LY3305677), a Weekly-Dose Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist, in Subjects with Overweight or Obesity

Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial

Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial

Efficacy and Safety of Orlistat in Chinese Obese Patients

A Phase 2 Randomised Controlled Trial of Mazdutide in Chinese Overweight Adults or Adults with Obesity

Efficacy of Meal Replacement Products on Weight and Glycolipid Metabolism Management: A 90-Day Randomized Controlled Trial in Adults with Obesity

Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial

Effects of Once-Weekly Semaglutide in Obese/overweight Patients: A Systematic Review and Meta-Analysis

Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial

Effectiveness and safety of Daixie Decoction granules combined with metformin for the treatment of T2DM patients with obesity: study protocol for a randomized, double-blinded, placebo-controlled, multicentre clinical trial

Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial

Efficacy of First-Time Intragastric Balloon in Weight Loss: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials

Effect of Intragastric Botulinum Type A Injection Combined with a Low-Calorie High-Protein Diet in Adults with Overweight or Obesity

Short-Term Efficacy of Endoscopic Sleeve Gastroplasty Versus Intragastric Balloon Insertion for Obesity: An Indonesian, Single-Center, Retrospective Cohort Study